Medical network - February 16 New Year new atmosphere, and it was time to do the summary of the past year inventory. At present, each big multinational drug companies posted results in 2016. Major multinational pharmaceutical giant in the past year revenue? What surprise and bring us?
▍ generally enhance performance in 2016
The blue part of results have been published 2016 parker multinational pharmaceutical companies for the finishing, found that although the present there are some companies did not posted in 2016, published each big multinational drug companies generally enhance performance in 2016, and 2016 revenue more than billions dollars.
In the past, it seems, multinational drug companies the throne of the big three are basically, led by Pfizer, roche, novartis, however, judging from the results of published, in 2016, Johnson & Johnson held the top seems to have no suspense. According to Johnson & Johnson reported, its revenue is as high as $2016 in 71.89 billion, far more than for the second, three, four, roche, novartis, Pfizer its competitive power to be reckoned with.
In addition, 2016 revenue growth rate more than 10% of the multinational pharmaceutical companies with Pfizer, abbvie, BMS, the new base. Among them, the new base for new billion-dollar club members, its star product anti-tumor medicine drug lenalidomide's sales hit us $6.974 billion in 2016, the company full-year revenue of $11.185 billion, rose as high as 22.11%, ranking rose sharply, as a rising star in the multinational pharmaceutical companies.
The following is a part of the multinational pharmaceutical companies in 2016 revenue:
(source: the drug companies earnings in 2016, not including enterprise has yet to be announced)
▍ multinational drug companies are bullish on the Chinese market
In 2016, many multinational companies in the collective experience after the separation of non-core business such as plate adjustment, accomplished its performance generally improved in 2016, data from the above chart can be very intuitive. And emerging markets, represented by China in the elysian fields become the multinational drug firms favoured by at the same time, also with good profit and larger development space.
From several multinational pharmaceutical giant data results in 2016, the Chinese market has become the indispensable part of the corporate performance. Astrazeneca, for example, in the United States, Europe, Japan, Canada and so on the performance of the mature markets down across, in emerging markets, including China, Brazil, India, Mexico, Russia, Turkey, etc.), but has a remarkable performance, especially in the Chinese market sales revenue as much as $2.636 billion, accounting for 45% of all emerging markets, astrazeneca global performance strong support.
IMS issued industry report, forecast in the next few years the growth gap between mature markets and emerging pharmaceutical market will continue to increase. Report to 2018 years ago, the emerging pharmaceutical pharmaceutical sales market is expected to account for one-third of the total cost of the global market (market is neck and neck with the United States), and has contributed nearly 60% of market value growth (not including rebate and discount). The focus of the global market growth potential has clearly in favour of the new medical market.
In addition, China's new drug approval speed will bring new business opportunities for multinational pharmaceutical companies. A multinational drug company executives said in an interview with the media, the original foreign drugs into China, it usually takes 5-8 years of application period, resulting in a large number of new drug approval lag, speed up after the original accumulation of no can quickly introduce new drugs to enter the Chinese market, as a new market growth companies.
▍ Chinese drug companies are actively "go out"
In recent years, the multinational pharmaceutical companies are increasing in China at the same time, some powerful local drug firms are holding overseas, through the active overseas investment layout to take in the future international dispute.
Recently, the Shanghai and huang pharmaceutical co., LTD. Mainly products bile ning, obtain health Canada natural drugs and non-prescription drugs listed license approved by the bureau. Previously, the domestic guangzhou qixing pharmaceutical co., LTD., guangzhou xiangxue pharmaceutical co., LTD., tasly pharmaceutical group co., LTD., and other enterprises also have related TCM products sold in Canada, let everybody see another dawn of outside of traditional Chinese medicine.
In the yesterday (15 February), broad medicine group and fortune 2017 "fortune" global BBS (guangzhou) signed strategic cooperation, the broad medicine group invited as 2017 "fortune" global strategic partner of BBS, will undertake the "medical health points BBS".
Wide medicine group as one of China's leading drug companies, is also with practical action to speed up the pace of internationalization. Wide medicine group chairman Li Chuyuan said in an interview with the media after the meeting, broad medicine group cooperation with "fortune" BBS is part of the company's international strategy. Specifically, through cooperation with fortune can use wealth group's influence to speed up the broad medicine group, the implementation of the strategy of internationalization, make broad medicine group, wang Lao ji's herbal teas and baiyun mountain drinking water products go out as soon as possible.
According to the Chinese health care, according to data from the chamber of commerce in 2016, Chinese medicine and health products import and export of $103.4 billion, up 0.73% from a year earlier. If eliminate the effects of exchange rate conversion into RMB statistics, in 2016, medicine, 7.12% of China's foreign trade growth and export growth of 4.41%, imports rose 10.42%, led the overall level of foreign trade in our country.
Although external demand in major economies, emerging markets underpowered, price competition, and many other factors, 2016 medical foreign trade import and export into the low speed growth, however, we see the medicine export structure to optimize, the acceleration of enterprise internationalization, new development of kinetic energy is accumulated, medicine and general development situation of foreign trade was positive.
At present, many Chinese drug firms in developing the domestic market at the same time, also actively to the international. We look forward to, the Chinese native medicine companies one day, also will appear with huawei enterprise was born, famous all over the world! |
